866-997-4948(US-Canada Toll Free)

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Published By :

Transparency Market Research

Published Date : Aug 2018

Category :

Pharmaceutical

No. of Pages : 185 Pages

Glaucoma Therapeutics Market: Scope and Methodology

This report analyzes the current and future prospects of the global glaucoma therapeutics market. The report comprises a comprehensive executive summary, including a market snapshot that provides overall information of various segments. The research is a combination of primary and secondary research. Primary research formed the bulk of the research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2016 to 2026, considering the macro and micro environmental factors. Growth rates for each segment within the global glaucoma therapeutics market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the overview section. The report also provides insights into the key trends of the glaucoma therapeutics market such as growth in geriatric and diabetic populations, increase in health care spending, and innovative drug combinations. Key market indicators influencing the global glaucoma therapeutics market, including cost constraints and regulatory landscape, have been taken into consideration. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global glaucoma therapeutics market.

Market revenue in terms of US$ Mn for the period between 2016 and 2026 along with the compound annual growth rate (CAGR %) from 2018 to 2026 are provided for all the segments, considering 2017 as the base year. The year-on-year growth of the global glaucoma therapeutics market for each segment is also reflected. Additionally, market-related factors such as favorable reimbursement scenario, gene replacement therapy, side effects associated with glaucoma drugs, and historical year-on-year growth have been taken into consideration while estimating the market size.

Glaucoma Therapeutics Market: Segmentation

Based on drug class, the global glaucoma therapeutics market has been segmented into prostaglandins, beta blockers, alpha agonists, carbonic anhydrase inhibitors, combination medications, and cholinergics. In terms of end-user, the market has been classified into hospitals, ophthalmic clinics, and ambulatory surgical centers. The hospitals segment is expected to dominate the market during the forecast period.

In terms of region, the global glaucoma therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been divided into major countries/sub-regions. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, Japan, India, Brazil, GCC Countries, South Africa, and Mexico.

Glaucoma Therapeutics Market: Competitive Landscape

The report also profiles major players in the global glaucoma therapeutics market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Allergan plc, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Santen Pharmaceuticals Co. Ltd., Valeant Pharmaceuticals International, Inc., and Aerie Pharmaceuticals, Inc.

The global glaucoma therapeutics Market has been segmented as follows:

Global Glaucoma Therapeutics Market, by Drug Class

  • Prostaglandins
  • Beta Blockers
  • Alpha Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Medications
  • Cholinergics

Global Glaucoma therapeutics Market, by End-user

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

 Global Glaucoma therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Australia & New Zealand
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Glaucoma Therapeutics Market

4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Glaucoma Therapeutics Market Analysis and Forecasts, 2016–2026
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1. Value Chain Analysis
5.2. Disease Prevalence & Incidence Rate, by Region
5.3. Healthcare Industry Overview
5.4. Pipeline Analysis

6. Global Glaucoma Therapeutics Market Analysis and Forecasts, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2016–2026
6.3.1. Prostaglandins
6.3.2. Beta Blockers
6.3.3. Alpha Agonists
6.3.4. Carbonic Anhydrase Inhibitors
6.3.5. Combination Medications
6.3.6. Cholinergics
6.4. Market Attractiveness, by Drug Class

7. Global Glaucoma Therapeutics Market Analysis and Forecasts, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2016–2026
7.3.1. Hospitals
7.3.2. Ophthalmic Clinics
7.3.3. Ambulatory Surgical Centers
7.4. Market Attractiveness, by End-user

8. Global Glaucoma Therapeutics Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region

9. North America Glaucoma Therapeutics Market Analysis and Forecast
9.1. Introduction
9.2. Market Value Forecast, by Drug Class, 2016–2026
9.2.1. Prostaglandins
9.2.2. Beta Blockers
9.2.3. Alpha Agonists
9.2.4. Carbonic Anhydrase Inhibitors
9.2.5. Combination Medications
9.2.6. Cholinergics
9.3. Market Value Forecast, by End-user, 2016–2026
9.3.1. Hospitals
9.3.2. Ophthalmic Clinics
9.3.3. Ambulatory Surgical Centers
9.4. Market Value Forecast, by Country, 2016–2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By End-user
9.5.3. By Country

10. Europe Glaucoma Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Market Value Forecast, by Drug Class, 2016–2026
10.2.1. Prostaglandins
10.2.2. Beta Blockers
10.2.3. Alpha Agonists
10.2.4. Carbonic Anhydrase Inhibitors
10.2.5. Combination Medications
10.2.6. Cholinergics
10.3. Market Value Forecast, by End-user, 2016–2026
10.3.1. Hospitals
10.3.2. Ophthalmic Clinics
10.3.3. Ambulatory Surgical Centers
10.4. Market Value Forecast, by Country/Sub-region, 2016–2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By End-user
10.5.3. By Country/Sub-region

11. Asia Pacific Glaucoma Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast, by Drug Class, 2016–2026
11.2.1. Prostaglandins
11.2.2. Beta Blockers
11.2.3. Alpha Agonists
11.2.4. Carbonic Anhydrase Inhibitors
11.2.5. Combination Medications
11.2.6. Cholinergics
11.3. Market Value Forecast, by End-user, 2016–2026
11.3.1. Hospitals
11.3.2. Ophthalmic Clinics
11.3.3. Ambulatory Surgical Centers
11.4. Market Value Forecast, by Country/Sub-region, 2016–2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By End-user
11.5.3. By Country/Sub-region

12. Latin America Glaucoma Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast, by Drug Class, 2016–2026
12.2.1. Prostaglandins
12.2.2. Beta Blockers
12.2.3. Alpha Agonists
12.2.4. Carbonic Anhydrase Inhibitors
12.2.5. Combination Medications
12.2.6. Cholinergics
12.3. Market Value Forecast, by End-user, 2016–2026
12.3.1. Hospitals
12.3.2. Ophthalmic Clinics
12.3.3. Ambulatory Surgical Centers
12.4. Market Value Forecast, by Country/Sub-region, 2016–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By End-user
12.5.3. By Country/Sub-region

13. Middle East & Africa Glaucoma Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast, by Drug Class, 2016–2026
13.2.1. Prostaglandins
13.2.2. Beta Blockers
13.2.3. Alpha Agonists
13.2.4. Carbonic Anhydrase Inhibitors
13.2.5. Combination Medications
13.2.6. Cholinergics
13.3. Market Value Forecast, by End-user, 2016–2026
13.3.1. Hospitals
13.3.2. Ophthalmic Clinics
13.3.3. Ambulatory Surgical Centers
13.4. Market Value Forecast, by Country/Sub-region, 2016–2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By End-user
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Market Player - Competition Matrix
14.2. Market Share Analysis, by Company (2016)
14.3. Company Profiles
14.3.1. Allergan plc
14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2 Financial Overview
14.3.1.3 Product Portfolio
14.3.1.4 SWOT Analysis
14.3.1.5 Strategic Overview
14.3.2. Merck & Co., Inc.
14.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2 Financial Overview
14.3.2.3 Product Portfolio
14.3.2.4 SWOT Analysis
14.3.2.5 Strategic Overview
14.3.3. Novartis AG
14.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2 Financial Overview
14.3.3.3 Product Portfolio
14.3.3.4 SWOT Analysis
14.3.3.5 Strategic Overview
14.3.4. Pfizer Inc.
14.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2 Financial Overview
14.3.4.3 Product Portfolio
14.3.4.4 SWOT Analysis
14.3.4.5 Strategic Overview
14.3.5. Santen Pharmaceuticals Co. Ltd.
14.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2 Financial Overview
14.3.5.3 Product Portfolio
14.3.5.4 SWOT Analysis
14.3.5.5 Strategic Overview
14.3.6. Valeant Pharmaceuticals International, Inc.
14.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2 Financial Overview
14.3.6.3 Product Portfolio
14.3.6.4 SWOT Analysis
14.3.6.5 Strategic Overview
14.3.7. Aerie Pharmaceuticals Inc.
14.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2 Product Portfolio
14.3.7.3 SWOT Analysis
14.3.7.4 Strategic Overview

List of Table

Table 01: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 03: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Region, 2016–2026
Table 04: North America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 05: North America Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 06: North America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 07: U.S. Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 08: U.S. Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 09: Canada Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 10: Canada Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 11: Europe Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 12: Europe Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 13: Europe Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14: U.K. Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 15: U.K. Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 16: Germany Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 17: Germany Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 18: France Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 19: France Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 20: Spain Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 21: Spain Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 22: Italy Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 23: Italy Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 24: Rest of Europe Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 25: Rest of Europe Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 26: Asia Pacific Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 27: Asia Pacific Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 28: Asia Pacific Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 29: Japan Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 30: Japan Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 31: China Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 32: China Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 33: India Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 34: India Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 35: Australia & New Zealand Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 36: Australia & New Zealand Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 37: Rest of APAC Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 38: Rest of APAC Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 39: Latin America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 40: Latin America Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 41: Latin America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 42: Brazil Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 43: Brazil Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 44: Mexico Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 45: Mexico Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 46: Rest of LATAM Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 47: Rest of LATAM Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 48: Middle East & Africa Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 49: Middle East & Africa Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 50: Middle East & Africa Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 51: GCC Countries Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 52: GCC Countries Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 53: South Africa Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 54: South Africa Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 55: Rest of MEA Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 56: Rest of MEA Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026

List of Chart

Figure 01: Global Glaucoma Therapeutics Market Snapshot
Figure 02: Global Glaucoma Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2026
Figure 03: Market Value Share, by Drug Class (2017)
Figure 04: Market Value Share, by End-user (2017)
Figure 05: Market Value Share, by Region (2017)
Figure 06: Global Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 07: Global Prostaglandins Market Revenue (US$ Mn), 2016–2026
Figure 08: Global Beta Blockers Market Revenue (US$ Mn), 2016–2026
Figure 09: Global Alpha Agonist Market, Revenue (US$ Mn), 2016–2026
Figure 10: Global Carbonic Anhydrase Inhibitor (CAI) Market, Revenue (US$ Mn), 2016–2026
Figure 11: Global Combination Medications Market, Revenue (US$ Mn), 2016–2026
Figure 12: Global Cholinergic Market, Revenue (US$ Mn), 2016–2026
Figure 13: Global Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 14: Global Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 15: Global Hospitals Market Revenue (US$ Mn), 2016–2026
Figure 16: Global Ophthalmic Clinics Market Revenue (US$ Mn), 2016–2026
Figure 17: Global Ambulatory Surgical Centers Market Revenue (US$ Mn), 2016–2026
Figure 18: Global Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 19: Global Glaucoma Therapeutics Market Value Share Analysis, by Region, 2017 and 2026
Figure 20: Global Glaucoma Therapeutics Market Attractiveness Analysis, by Region, 2018–2026
Figure 21: North America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 22: North America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country
Figure 23: North America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 24: North America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 25: North America Glaucoma Therapeutics Market, by Country, 2017 and 2026
Figure 26: North America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 27: North America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 28: Europe Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 29: Europe Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-Region
Figure 30: Europe Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 31: Europe Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 32: Europe Glaucoma Therapeutics Market, by Country/Sub-region
Figure 33: Europe Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 34: Europe Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 35: Asia Pacific Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 36: Asia Pacific Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-Region
Figure 37: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 38: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 39: Asia Pacific Glaucoma Therapeutics Market, by Country/Sub-region
Figure 40: Asia Pacific Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 41: Asia Pacific Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 42: Latin America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 43: Latin America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region
Figure 44: Latin America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 45: Latin America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 46: North America Glaucoma Therapeutics Market, by Country/Sub-region
Figure 47: Latin America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 48: Latin America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 49: Middle East & Africa Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 50: Middle East & Africa Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region
Figure 51: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 52: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 53: Middle East & Africa Glaucoma Therapeutics Market, by Country/Sub-region
Figure 54: Middle East & Africa Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 55: Middle East & Africa Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 56: Global Glaucoma Therapeutics Market Share Analysis, by Company (2017)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *